← board
XRTX
distress 6/10 · elevated risk$2.14+6%today-61% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.1 yrs
Shares 1y
—
Price & events
-22.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+6.5%
1D
+1.4%
1W
+2.9%
1M
-22.7%
3M
-24.9%
6M
-52.4%
1Y
-75.5%
2Y
—
5Y
-99.9%
All
Overview
- Market Cap
- $27.80M
- Volume
- 9.43K
- 52 Week Range
- $1.73 – $5.50
- Total Shares
- 12.99M
- Float Shares
- 1.37M
- Short %
- 1.47%
- % Held by Insiders
- 8.22%
- % Held by Institutions
- 2.23%
- RVOL
- 0.73x
- Beta
- 0.17
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-20XORTX Therapeutics (XRTX) Investor presentation Summary - Quartr
- 2026-07-20XORTX Therapeutics (XRTX) Q4 2024 earnings summary - Quartr
- 2026-07-12XORTX Therapeutics (XRTX) Rallies 3.3% as Biotech Sector Gains Momentum - Money Flow - dars.gov.et
- 2026-07-12XORTX Therapeutics (XRTX) Gains 3.33% as Biotech Momentum Builds - Descending Triangle - dars.gov.et
- 2026-07-12XORTX Therapeutics (XRTX) Gains 3.33% as Biotech Momentum Builds - TICK Divergence - dars.gov.et
- 2026-07-09XRTX Q1 2024 Earnings: Pre‑Revenue Biotech Reports EPS Miss as Clinical Pipeline Advances - Earnings Cycle Outlook - dars.gov.et
- 2026-07-07Xortx Therapeutics updates investors on kidney disease focus - Ad-hoc-news.de
- 2026-07-07XORTX Therapeutics Company Profile & Introduction - Moomoo
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.